Intra-Cellular Therapies, Inc. (ITCI)
USD 131.87
(0.0%)
USD 131.87
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 136.87 Million USD | 38.66% |
| 2022 | 98.71 Million USD | 37.04% |
| 2021 | 72.03 Million USD | 19.15% |
| 2020 | 60.45 Million USD | 7.61% |
| 2019 | 56.17 Million USD | 42.26% |
| 2018 | 39.49 Million USD | 131.63% |
| 2017 | 17.04 Million USD | 27.23% |
| 2016 | 13.4 Million USD | 70.48% |
| 2015 | 7.86 Million USD | -25.54% |
| 2014 | 10.55 Million USD | 54.48% |
| 2013 | 6.83 Million USD | 140.67% |
| 2012 | 2.83 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 147.53 Million USD | 7.79% |
| 2024 Q3 | 179.61 Million USD | 2.12% |
| 2024 Q2 | 175.89 Million USD | 19.22% |
| 2023 Q4 | 136.87 Million USD | 17.0% |
| 2023 FY | 136.87 Million USD | 38.66% |
| 2023 Q1 | 94.54 Million USD | -4.22% |
| 2023 Q2 | 106.51 Million USD | 12.65% |
| 2023 Q3 | 116.98 Million USD | 9.83% |
| 2022 Q3 | 96.57 Million USD | 7.66% |
| 2022 Q1 | 75.83 Million USD | 5.27% |
| 2022 FY | 98.71 Million USD | 37.04% |
| 2022 Q4 | 98.71 Million USD | 2.21% |
| 2022 Q2 | 89.7 Million USD | 18.3% |
| 2021 Q4 | 72.03 Million USD | 2.58% |
| 2021 Q2 | 72.11 Million USD | 15.68% |
| 2021 FY | 72.03 Million USD | 19.15% |
| 2021 Q3 | 70.21 Million USD | -2.62% |
| 2021 Q1 | 62.33 Million USD | 3.12% |
| 2020 Q4 | 60.45 Million USD | -2.33% |
| 2020 FY | 60.45 Million USD | 7.61% |
| 2020 Q3 | 61.89 Million USD | 0.81% |
| 2020 Q2 | 61.4 Million USD | 20.88% |
| 2020 Q1 | 50.79 Million USD | -9.59% |
| 2019 FY | 56.17 Million USD | 42.26% |
| 2019 Q2 | 53.09 Million USD | -2.33% |
| 2019 Q3 | 53.64 Million USD | 1.03% |
| 2019 Q4 | 56.17 Million USD | 4.73% |
| 2019 Q1 | 54.35 Million USD | 37.65% |
| 2018 Q3 | 31.96 Million USD | 47.38% |
| 2018 Q1 | 22.45 Million USD | 31.67% |
| 2018 FY | 39.49 Million USD | 131.63% |
| 2018 Q4 | 39.49 Million USD | 23.56% |
| 2018 Q2 | 21.68 Million USD | -3.4% |
| 2017 Q2 | 9.87 Million USD | -48.75% |
| 2017 Q1 | 19.26 Million USD | 43.76% |
| 2017 Q4 | 17.04 Million USD | 15.59% |
| 2017 FY | 17.04 Million USD | 27.23% |
| 2017 Q3 | 14.75 Million USD | 49.39% |
| 2016 Q3 | 143.25 Million USD | 561.98% |
| 2016 Q4 | 13.4 Million USD | -90.65% |
| 2016 Q1 | 10.91 Million USD | 38.89% |
| 2016 FY | 13.4 Million USD | 70.48% |
| 2016 Q2 | 21.64 Million USD | 98.22% |
| 2015 Q3 | 11.26 Million USD | 14.53% |
| 2015 Q4 | 7.86 Million USD | -30.24% |
| 2015 Q2 | 9.83 Million USD | -33.31% |
| 2015 Q1 | 14.75 Million USD | 39.74% |
| 2015 FY | 7.86 Million USD | -25.54% |
| 2014 Q4 | 10.55 Million USD | 195.09% |
| 2014 Q1 | 3.91 Million USD | -42.76% |
| 2014 Q2 | 2.73 Million USD | -29.97% |
| 2014 FY | 10.55 Million USD | 54.48% |
| 2014 Q3 | 3.57 Million USD | 30.6% |
| 2013 Q2 | 33.03 Thousand USD | 26.22% |
| 2013 FY | 6.83 Million USD | 140.67% |
| 2013 Q4 | 6.83 Million USD | -12.1% |
| 2013 Q1 | 26.17 Thousand USD | -99.08% |
| 2013 Q3 | 7.77 Million USD | 23436.76% |
| 2012 Q4 | 2.83 Million USD | 0.0% |
| 2012 FY | 2.83 Million USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Collegium Pharmaceutical, Inc. | 947.87 Million USD | 85.56% |
| Embecta Corp. | 2.03 Billion USD | 93.278% |
| ANI Pharmaceuticals, Inc. | 471.67 Million USD | 70.982% |
| Dynavax Technologies Corporation | 375.02 Million USD | 63.503% |
| Esperion Therapeutics, Inc. | 660.79 Million USD | 79.287% |
| Pacira BioSciences, Inc. | 704.25 Million USD | 80.565% |
| PainReform Ltd. | 2.69 Million USD | -4986.25% |
| Aquestive Therapeutics, Inc. | 163.9 Million USD | 16.494% |
| Sunshine Biopharma, Inc. | 6.13 Million USD | -2129.315% |
| SCYNEXIS, Inc. | 55.45 Million USD | -146.837% |
| China SXT Pharmaceuticals, Inc. | 9.19 Million USD | -1388.276% |
| Cosmos Health Inc. | 30.25 Million USD | -352.428% |
| Journey Medical Corporation | 56.49 Million USD | -142.254% |
| Sunshine Biopharma, Inc. | 6.13 Million USD | -2129.315% |
| Safety Shot Inc | 3.89 Million USD | -3416.687% |
| Alpha Teknova, Inc. | 38.55 Million USD | -255.039% |
| Bright Green Corporation | 6.43 Million USD | -2025.953% |
| Procaps Group, S.A. | 462.06 Million USD | 70.378% |
| Theratechnologies Inc. | 98.63 Million USD | -38.76% |
| Harrow Health, Inc. | 241.75 Million USD | 43.384% |
| Sonoma Pharmaceuticals, Inc. | 8.75 Million USD | -1463.168% |
| Biofrontera Inc. | 23.13 Million USD | -491.516% |
| DURECT Corporation | 30.4 Million USD | -350.145% |
| Supernus Pharmaceuticals, Inc. | 487.46 Million USD | 71.922% |
| Cronos Group Inc. | 43.73 Million USD | -212.948% |
| OptiNose, Inc. | 194.33 Million USD | 29.57% |
| Ironwood Pharmaceuticals, Inc. | 817.36 Million USD | 83.255% |
| Kala Pharmaceuticals, Inc. | 48.44 Million USD | -182.529% |
| RedHill Biopharma Ltd. | 20.97 Million USD | -552.446% |
| Organogenesis Holdings Inc. | 181.36 Million USD | 24.532% |
| Guardion Health Sciences, Inc. | 3.77 Million USD | -3528.477% |
| Cumberland Pharmaceuticals Inc. | 52.51 Million USD | -160.626% |
| Radius Health, Inc. | 804.29 Million USD | 82.982% |
| Universe Pharmaceuticals INC | 13.75 Million USD | -895.112% |
| ProPhase Labs, Inc. | 42.54 Million USD | -221.716% |
| Phibro Animal Health Corporation | 725.54 Million USD | 81.135% |
| Procaps Group S.A. | 462.06 Million USD | 70.378% |
| Alvotech | 1.88 Billion USD | 92.73% |
| TherapeuticsMD, Inc. | 14.02 Million USD | -876.116% |
| Viatris Inc. | 27.21 Billion USD | 99.497% |
| Rockwell Medical, Inc. | 30.88 Million USD | -343.206% |
| Aytu BioPharma, Inc. | 90.37 Million USD | -51.441% |
| SIGA Technologies, Inc. | 57.97 Million USD | -136.077% |
| Tilray Brands, Inc. | 892.11 Million USD | 84.658% |
| Lifecore Biomedical, Inc. | 219.8 Million USD | 37.729% |
| Shineco, Inc. | 47.6 Million USD | -187.534% |
| PetIQ, Inc. | 645.22 Million USD | 78.787% |
| Regencell Bioscience Holdings Limited | 219.51 Thousand USD | -62252.4% |
| Incannex Healthcare Limited | 5.83 Million USD | -2247.702% |
| Neurocrine Biosciences, Inc. | 1.01 Billion USD | 86.573% |
| Alimera Sciences, Inc. | 107.35 Million USD | -27.495% |
| Silver Spike Investment Corp. | 3 Million USD | -4447.465% |
| Assertio Holdings, Inc. | 148.41 Million USD | 7.779% |
| Shuttle Pharmaceuticals Holdings, Inc. | 1.89 Million USD | -7119.068% |
| Petros Pharmaceuticals, Inc. | 21.31 Million USD | -542.111% |
| Clever Leaves Holdings Inc. | 7.02 Million USD | -1848.064% |
| Cyclo Therapeutics, Inc. | 8.49 Million USD | -1512.043% |
| Avadel Pharmaceuticals plc | 173.38 Million USD | 21.06% |
| Hempacco Co., Inc. | 18.82 Million USD | -627.171% |
| Talphera, Inc. | 6.29 Million USD | -2076.01% |
| Alvotech | 1.88 Billion USD | 92.73% |
| Eagle Pharmaceuticals, Inc. | 172.6 Million USD | 20.7% |
| Lantheus Holdings, Inc. | 835.25 Million USD | 83.613% |
| Currenc Group, Inc. | 177.67 Million USD | 22.966% |
| Kamada Ltd. | 109.96 Million USD | -24.464% |
| Indivior PLC | 1.95 Billion USD | 92.985% |
| Evoke Pharma, Inc. | 9.64 Million USD | -1318.634% |
| Flora Growth Corp. | 17.22 Million USD | -694.745% |
| Cyclo Therapeutics, Inc. | 8.49 Million USD | -1512.043% |
| Evolus, Inc. | 209.68 Million USD | 34.726% |
| HUTCHMED (China) Limited | 536.38 Million USD | 74.483% |
| Amphastar Pharmaceuticals, Inc. | 873.49 Million USD | 84.331% |
| Akanda Corp. | 12.66 Million USD | -980.371% |